0001193125-20-103920.txt : 20200410 0001193125-20-103920.hdr.sgml : 20200410 20200410164555 ACCESSION NUMBER: 0001193125-20-103920 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200410 DATE AS OF CHANGE: 20200410 EFFECTIVENESS DATE: 20200410 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP CENTRAL INDEX KEY: 0000875622 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113054851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 000-19879 FILM NUMBER: 20787064 BUSINESS ADDRESS: STREET 1: 35 WILBUR ST CITY: LYNBROOK STATE: NY ZIP: 11563 BUSINESS PHONE: 5165937000 MAIL ADDRESS: STREET 1: 35 WILBUR STREET CITY: LYNBROOK STATE: NY ZIP: 11563 15-12G 1 d917342d1512g.htm FORM 15-12G Form 15-12G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 000-19879

 

 

BIOSPECIFICS TECHNOLOGIES CORP.

(Exact name of registrant as specified in its charter)

 

 

2 Righter Parkway, Delaware Corporate Center II, Wilmington, DE 19803

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Series B Junior Participating Preferred Stock Purchase Rights (1)

(Title of each class of securities covered by this Form)

Common Stock ($0.001 par value)

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)   ☒
Rule 12g-4(a)(2)   ☐
Rule 12h-3(b)(1)(i)   ☐
Rule 12h-3(b)(1)(ii)   ☐
Rule 15d-6   ☐
Rule 15d-22(b)   ☐

 

(1)

These Series B Junior Participating Preferred Stock Purchase Rights (the “Expired Rights”) were issued in connection with BioSpecifics Technologies Corp.’s execution of a Rights Agreement, dated as of May 14, 2002, as amended on June 19, 2003, and as further amended on February 3, 2011, March 5, 2014, May 27, 2016, May 11, 2018, and April 10, 2020 (the “Rights Agreement”), between BioSpecifics Technologies Corp. and Worldwide Stock Transfer, LLC (as successor in interest to OTC Corporate Transfer Service Company) as Rights Agent. The Rights Agreement expired on April 10, 2020 and, accordingly, the Rights Agreement and the Expired Rights are no longer in effect. BioSpecifics Technologies Corp. previously filed a Registration Statement on Form 8-A12G to register the Expired Rights on May 30, 2002.

Approximate number of holders of record as of the certification or notice date: None

Pursuant to the requirements of the Securities Exchange Act of 1934, BioSpecifics Technologies Corp. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

    BIOSPECIFICS TECHNOLOGIES CORP.
    (Registrant)
Date: April 10, 2020   By:  

/s/ Carl A. Valenstein

   

Carl A. Valenstein

Corporate Secretary